. Author manuscript; available in PMC: 2022 Feb 8.

Published in final edited form as: J Am Acad Dermatol. 2019 Dec 17;82(6):1435–1444. doi: 10.1016/j.jaad.2019.12.020

Table 3:

Suggested Treatment Recommendations for Cases Interpreted as Moderate or Severe Dysplasia by Pathologists’ Characteristics.

		Moderate dysplasia					Severe dysplasia

	No. case readings	None	≤ .5	.5–1	≥ 1	P-value	None	≤ .5	.5–1	≥ 1	P-value
	No. case readings	99	420	79	3	P-value	10	134	193	16	P-value

Affiliation with academic medical center
No	6432	59 (14%)	316 (72%)	60 (14%)	1 (0%)	<0.01	6 (2%)	99 (40%)	130 (53%)	12 (5%)	0.51
Yes	2544	40 (24%)	104 (63%)	19 (12%)	2 (1 %)		4 (4%)	35 (33%)	63 (59%)	4 (4%)
Fellowship or board certified in dermatopathology
No	5424	35 (10%)	235 (69%)	70 (20%)	3 (1 %)	<0.001	6 (3%)	67 (35%)	107 (55%)	14 (7%)	0.03
Yes	3552	64 (25%)	185 (72%)	9 (3%)	0 (0%)		4 (3%)	67 (42%)	86 (54%)	2 (1 %)
Years interpreting melanocytic skin lesions
< 10 years	3552	39 (16%)	182 (73%)	27 (11%)	2 (1 %)	0.34	2 (1 %)	44 (28%)	100 (65%)	9 (6%)	<0.01
10 years +	5424	60 (17%)	238 (68%)	52 (15%)	1 (0%)		8 (4%)	90 (45%)	93 (47%)	7 (4%)
Percent of caseload is melanocytic skin lesions
< 10 percent	3792	27 (11%)	173 (72%)	40 (17%)	0 (0%)	<0.01	4 (3%)	52 (36%)	83 (57%)	6 (4%)	0.87
≥ 10 percent	5184	72 (20%)	247 (68%)	39 (11%)	3 (1 %)		6 (3%)	82 (39%)	110 (53%)	10 (5%)